STOCK TITAN
  1. Home
  2. News
  3. GERN

Geron Corp. - GERN STOCK NEWS

Welcome to our dedicated news page for Geron (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geron's position in the market.

News
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
Rhea-AI Summary
Geron Corporation (Nasdaq: GERN) announced data from its IMerge Phase 3 clinical trial evaluating telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes patients, presenting significant clinical benefits and safety profile at the ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
acquisition clinical trial
-
News
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
Rhea-AI Summary
Geron Corporation (GERN) achieves 50% enrollment in Phase 3 IMpactMF clinical trial for imetelstat in relapsed/refractory myelofibrosis patients. Interim analysis expected in H1 2025, final analysis in H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
clinical trial
-
News
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
Rhea-AI Summary
Geron Corporation (GERN) announced the publication of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication in The Lancet validates the study's importance within the field and reaches hematologists and other providers globally with potentially practice-changing results. Imetelstat is currently under regulatory review by the FDA and EMA for approval in transfusion-dependent anemia in patients with lower risk MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
acquisition clinical trial
News
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
Rhea-AI Summary
Geron Corporation (GERN) appoints Dr. Gaurav Aggarwal, a prominent investor in the life sciences sector, to its Board of Directors. Dr. Aggarwal brings extensive strategic leadership and a demonstrated track record in corporate strategy and capital formation. His appointment is expected to add tremendous value as the company looks forward to a potential commercial launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Geron Corporation (Nasdaq: GERN) Grants Stock Options to Newly Hired Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
none
-
News
Geron to Participate at Upcoming Investor Conferences in November
Rhea-AI Summary
Geron Corporation (GERN) to Present at Investor Conferences, Webcasts Available - GERN Stock News
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
conferences
News
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
Rhea-AI Summary
Geron Corporation announces publication of abstracts from the IMerge Phase 3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The abstracts highlight that imetelstat achieved transfusion independence (TI) in patients across different risk groups and mutational profiles. Nearly 20% of imetelstat-treated patients achieved sustained TI for over 1 year with a median duration of TI of more than 2 years and a median hemoglobin increase of more than 5 g/dL. Imetelstat demonstrated efficacy in patients reclassified as higher risk using molecular international prognostic scoring system (IPSS-M).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
acquisition clinical trial
-
News
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
Rhea-AI Summary
Geron Corporation reported business highlights and financial results for Q3 2023. Imetelstat, a telomerase inhibitor, is under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS. The FDA assigned a PDUFA action date of June 16, 2024. Planning is ongoing for a potential commercial launch in the U.S. in mid-2024. Geron has approximately $382 million on the balance sheet as of the end of the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
earnings
-
News
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
Rhea-AI Summary
Geron Corporation will release its Q3 2023 financial results and business highlights on November 2, 2023. A conference call will be held at 9:00 a.m. ET the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
earnings
News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Geron Corporation grants stock options to newly hired employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock GERN logo
Geron Corp.

Nasdaq:GERN

GERN Rankings

#1840 Ranked by Market Cap
#3292 Ranked by Stock Gains
N/A Ranked by Dividends

GERN Stock Data

2.14B
475.07M
0.09%
67.83%
7.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Foster City

About GERN

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.